ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...
A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...
A team of researchers has reported a breakthrough in making sperm cell precursors in vitro that could be used in a number of ...
DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...
To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have ...
To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results